Skip to content

Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail

Screening of Fibrosing and/or Viral Chronic Hepatopathies in Jail

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00453869
Acronym
SNIFF11
Enrollment
240
Registered
2007-03-29
Start date
2007-04-30
Completion date
2008-03-31
Last updated
2014-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis

Keywords

Liver fibrosis, Hepatitis B virus and C virus, FibroMeter, FibroScan®

Brief summary

The prevalence of chronic hepatopathies is high in jail. However, the medical care of these hepatopathies is few developed. This study is an observational, an epidemiologic (screening and prevalence of fibrosing hepatopathies) and an evaluating study for a better taking care of these hepatopathies in jail. The aims of the study will be to evaluate the diagnostic performance of the FibroMeter score in the screening of the hepatic fibrosis in persons with multiple risk factors for liver fibrosis (alcoholism, intravenous drug users, tattoo, and virological status) with FibroScan® as gold standard; to evaluate the feasibility of these different screening tools for chronic hepatopathies in jail and to evaluate the prevalence of the fibrosing hepatopathies with clinically significant fibrosis and theirs risk factors, alcohol and hepatitis B and hepatitis C viruses in population from Angers jail.

Detailed description

Primary outcome: Screening of clinically significant fibrosis with FibroMeter blood score. Screening for hepatitis B and hepatitis C viruses. Secondary outcome: Clinically significant fibrosis confirmed with FibroScan®. The means for this study are a clinical questionnaire, a virological screening, a blood score for liver fibrosis: FibroMeter according to cause of the fibrosis and FibroScan® is referent and independent examination. The expected results from this study are the knowledge of the prevalence of hepatopathies with hepatic fibrosis will be able to justify, possibly, a screening politic of them. This study will permit to evaluate the feasibility of noninvasive screening of the liver fibrosis in the goal to suppress the liver biopsy in a population having numerous drawbacks.

Interventions

OTHERliver fibrosis evaluation

Evaluation of liver fibrosis with blood test

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Person over 18, * All new inmates, for less than one month, in Angers jail, * To have a written informed consent.

Exclusion criteria

* No consent obtained from person, * Detention inferior to one month, * Person under 18.

Design outcomes

Primary

MeasureTime frameDescription
Liver fibrosis evaluationD0Evaluation of liver fibrosis with blood tests

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026